1. Home
  2. RAPP vs PHAR Comparison

RAPP vs PHAR Comparison

Compare RAPP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RAPP
  • PHAR
  • Stock Information
  • Founded
  • RAPP 2022
  • PHAR 1988
  • Country
  • RAPP United States
  • PHAR Netherlands
  • Employees
  • RAPP N/A
  • PHAR N/A
  • Industry
  • RAPP
  • PHAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • RAPP
  • PHAR Health Care
  • Exchange
  • RAPP Nasdaq
  • PHAR Nasdaq
  • Market Cap
  • RAPP 1.2B
  • PHAR 951.7M
  • IPO Year
  • RAPP 2024
  • PHAR N/A
  • Fundamental
  • Price
  • RAPP $25.33
  • PHAR $16.51
  • Analyst Decision
  • RAPP Strong Buy
  • PHAR Strong Buy
  • Analyst Count
  • RAPP 4
  • PHAR 3
  • Target Price
  • RAPP $46.50
  • PHAR $30.00
  • AVG Volume (30 Days)
  • RAPP 359.8K
  • PHAR 18.4K
  • Earning Date
  • RAPP 11-06-2025
  • PHAR 11-06-2025
  • Dividend Yield
  • RAPP N/A
  • PHAR N/A
  • EPS Growth
  • RAPP N/A
  • PHAR N/A
  • EPS
  • RAPP N/A
  • PHAR 0.00
  • Revenue
  • RAPP N/A
  • PHAR $362,274,000.00
  • Revenue This Year
  • RAPP N/A
  • PHAR $17.70
  • Revenue Next Year
  • RAPP N/A
  • PHAR $12.25
  • P/E Ratio
  • RAPP N/A
  • PHAR $2,895.69
  • Revenue Growth
  • RAPP N/A
  • PHAR 26.78
  • 52 Week Low
  • RAPP $6.43
  • PHAR $7.31
  • 52 Week High
  • RAPP $42.27
  • PHAR $17.76
  • Technical
  • Relative Strength Index (RSI)
  • RAPP 48.38
  • PHAR 54.67
  • Support Level
  • RAPP $23.75
  • PHAR $15.79
  • Resistance Level
  • RAPP $25.87
  • PHAR $17.67
  • Average True Range (ATR)
  • RAPP 1.92
  • PHAR 0.78
  • MACD
  • RAPP -0.24
  • PHAR 0.23
  • Stochastic Oscillator
  • RAPP 28.22
  • PHAR 63.78

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: